Systematic review and meta-analysis reveals risperidone reduces aggression in children with ADHD and disruptive behaviour disorders, indicating its effectiveness but also risks.
Risperidone augmentation reduces aggression and oppositional symptoms in children and adolescents with ADHD and comorbid DBDs. Nonetheless, risperidone is associated with risks of weight gain, elevated serum prolactin, and metabolic syndrome.
No takes yet. Share an insight, caveat, or question.
Penubarthi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: